Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> received FDA fast track designation for its lead candidate 64Cu-SAR-bisPSMA for PET imaging of prostate cancer lesions. Currently, 64Cu-SAR-bisPSMA is in phase 3 trial.</li>
<li>If approved, 64Cu-SAR-bisPSMA has the potential the best-in-class diagnostic as the product has improved lesion detection capability compared to existing prostate cancer diagnostics.</li>
<li>Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represents an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.</li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) received FDA fast track designation for its lead candidate 64Cu-SAR-bisPSMA for PET imaging of prostate cancer lesions. Currently, 64Cu-SAR-bisPSMA is in phase 3 trial.
If approved, 64Cu-SAR-bisPSMA has the potential the best-in-class diagnostic as the product has improved lesion detection capability compared to existing prostate cancer diagnostics.
Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represents an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.


Clarity Pharmaceuticals Ltd (CU6 AU): An Attractive Bet on Red Hot Radiopharmaceutical Field

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>In Q1 2024, Eli Lilly and Company achieved strong growth and strategic milestones, with revenue growing by 26% and new products increasing by nearly $1.8 billion in comparison to the same period last year.</li><li>The company's new products, primarily Mounjaro and Zepbound, primarily drove the growth.</li><li>Eli Lilly also accomplished various pipeline milestones during this period.</li></ul>

In Q1 2024, Eli Lilly and Company achieved strong growth and strategic milestones, with revenue growing by 26% and new products increasing by nearly $1.8 billion in comparison to the same period last year.The company's new products, primarily Mounjaro and Zepbound, primarily drove the growth.Eli Lilly also accomplished various pipeline milestones during this period.

Eli Lilly & Co: The Story Behind The Increasing Demand vs. Production of Orforglipron & Progress of Other Drugs! - Major Drivers

<ul><li>Eli Lilly and Company's Q4 2023 earnings showed a year of growth and advancement for the company.</li><li>Revenue increased by 20 percent for the full year and 28 percent for the most recent quarter, as seen in the company's newly launched portfolio gaining momentum.</li><li>Notably, the company received regulatory approvals for Zepbound, Jaypirca, Omvoh, Ebglyss in the EU, and an expanded label for Verzenio and two new indications for Jardiance within 2023.</li></ul>

Eli Lilly and Company's Q4 2023 earnings showed a year of growth and advancement for the company.Revenue increased by 20 percent for the full year and 28 percent for the most recent quarter, as seen in the company's newly launched portfolio gaining momentum.Notably, the company received regulatory approvals for Zepbound, Jaypirca, Omvoh, Ebglyss in the EU, and an expanded label for Verzenio and two new indications for Jardiance within 2023.

Eli Lilly & Company: Product pipeline evolution with focus on improved patient outcomes! - Major Drivers

<ul><li>Eli Lilly and Company delivered a positive result and managed an all-around beat in the last quarter.</li><li>The company reported a notable 37% increase in revenue compared to the same period in 2022.</li><li>Research and development expenses saw a 34% increase, primarily due to higher development expenses for late-stage assets and increased investments in early-stage research.</li></ul>

Eli Lilly and Company delivered a positive result and managed an all-around beat in the last quarter.The company reported a notable 37% increase in revenue compared to the same period in 2022.Research and development expenses saw a 34% increase, primarily due to higher development expenses for late-stage assets and increased investments in early-stage research.

Eli Lilly and Company: Expansion of Oncology Capabilities & Other Major Drivers

<ul><li>Eli Lilly and Company managed to surpass the revenue and earnings expectations of Wall Street.</li><li>Eli Lilly made progress on its ambitious manufacturing plan, advanced its R&D pipeline, and produced positive financial results.</li><li>Furthermore, Eli Lilly announced that commercial production in its Research Triangle Park facility in North Carolina has started supporting its incretin portfolio.</li></ul>

Eli Lilly and Company managed to surpass the revenue and earnings expectations of Wall Street.Eli Lilly made progress on its ambitious manufacturing plan, advanced its R&D pipeline, and produced positive financial results.Furthermore, Eli Lilly announced that commercial production in its Research Triangle Park facility in North Carolina has started supporting its incretin portfolio.

Eli Lilly and Company: Will The Acquisition Of DICE Therapeutics Become A Growth Catalyst? - Major Drivers

United States

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eli Lilly & (LLY UN)

Clarity Pharmaceuticals Ltd (CU6 AU): An Attractive Bet on Red Hot Radiopharmaceutical Field

Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a...

Tina Banerjee

Eli Lilly & Co: The Story Behind The Increasing Demand vs. Production of Orforglipron & Progress of Other Drugs! - Major Drivers

In Q1 2024, Eli Lilly and Company achieved strong growth and strategic milestones, with revenue growing by 26% and new products increasing by...

Baptista Research

Eli Lilly & Company: Product pipeline evolution with focus on improved patient outcomes! - Major Drivers

Eli Lilly and Company's Q4 2023 earnings showed a year of growth and advancement for the company. Revenue increased by 20 percent for the full...

Baptista Research

Eli Lilly and Company: Expansion of Oncology Capabilities & Other Major Drivers

Eli Lilly and Company delivered a positive result and managed an all-around beat in the last quarter. The company reported a notable 37% increase...

Baptista Research

Eli Lilly and Company: Will The Acquisition Of DICE Therapeutics Become A Growth Catalyst? - Major Drivers

Eli Lilly and Company managed to surpass the revenue and earnings expectations of Wall Street. Eli Lilly made progress on its ambitious...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)